Top Markets
#1 Doge Strategy Doge Strategy +953,314.18%
#2 Noon Noon +12,208.80%
#3 Siren Siren +112.06%
#4 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#5 Venom Venom +46.63%
#6 Gigachad Gigachad +28.15%
#7 Ontology Ontology +20.38%
#8 Scor Scor +18.84%
#9 Win Win +17.98%
#10 TRIA TRIA +17.79%
Coin of the day
Doge Strategy Doge Strategy
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Rang in Aktien #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Aktienkurs
$0.0416118
Marktkapitalisierung
$12.78M
Veränderung (1 Tag)
1.72%
Veränderung (1 Jahr)
-22.01%
Land
AU
Handel Noxopharm Limited (NOX)

Kategorie

Healthcare
Operative Marge für Noxopharm Limited (NOX)
Operative Marge zum March 2026 TTM: -532.32%
Laut den neuesten Finanzberichten und dem Aktienkurs von Noxopharm Limited beträgt die aktuelle operative Marge (TTM) -532.32%. Am Ende des Jahres 2024 lag die operative Marge bei -313.92%.
Historie der operativen Marge von Noxopharm Limited von 2016 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) -532.32% 55.59%
2025 -342.14% 8.99%
2024 -313.92% 13.69%
2023 -276.12% -1.43%
2022 -280.14% 7.54%
2021 -260.50% 31.83%
2020 -197.61% -52.69%
2019 -417.69% -63.54%
2018 -1,145.69% -55.34%
2017 -2,565.11% 0.00%
2016 0.00% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
41.30% -100.08%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
35.45% -100.07%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
24.95% -100.05%
US
UCB SA UCB SA
UCB SA
UCB.BR
25.32% -100.05%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.05%
AU
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.